Can ruxolitinib cream (Opzelura) completely cure vitiligo and its efficacy evaluation

Ruxolitinib cream (Opzelura) is a topicalJAK inhibitor that blocks span>Januskinase (JAK) signaling pathway inhibits the immune system from abnormally attacking melanocytes, thereby slowing or preventing the expansion of white spots. Its main function is to control disease activity and promote local pigment regeneration, rather than directly repairing all lost melanin. Therefore, it is more suitable as a treatment for controlling and improving vitiligo, rather than being regarded as a complete cure.

Clinical trials have shown that ruxolitinib cream can effectively promote pigment recovery in patients with localized vitiligo, and is especially effective in the treatment of small areas of white spots on the face and hands. After weeks to months of use, some patients can observe significant pigment regression, and some white spots can return to near-normal skin color. However, there are individual differences in efficacy, and the effect may be better in the early stage or the active stage of local inflammation, while the pigment recovery is limited in patients with long-term stable stage or extensive vitiligo.

Although ruxolitinib cream can improve local vitiligo, maintaining long-term efficacy is still a challenge. After stopping the drug, some patients may experience hypopigmentation or recurrence of white spots, suggesting that the drug is more of a control treatment than a radical cure. Therefore, doctors usually recommend continued observation during the white spot stabilization or pigment recovery stage, combined with local care, phototherapy or other auxiliary treatments to maintain the efficacy and reduce the risk of recurrence.

In clinical application, the efficacy of ruxolitinib cream is usually evaluated using indicators such as the degree of pigment regression, change in white spot area, and improvement in patient quality of life. Patients should follow the doctor's guidance, apply regularly according to the course of treatment, and have regular follow-up visits to evaluate the treatment effect. For patients with unsatisfactory efficacy or high risk of recurrence, comprehensive therapies, such as phototherapy or immunomodulatory therapy, can be combined to maximize pigment recovery and control the progression of vitiligo. Overall, ruxolitinib cream can significantly improve white spots, but it cannot yet achieve a complete cure. Long-term management and individualized treatment are still the key.

Reference materials:https://www.drugs.com/